Literature DB >> 1576144

Giant cell myocarditis: first report of disease recurrence in the transplanted heart.

W Gries1, D Farkas, G L Winters, M R Costanzo-Nordin.   

Abstract

A 51-year-old female underwent heart transplantation for endomyocardial biopsy-proved giant cell myocarditis complicated by rapidly progressive congestive heart failure unresponsive to immunosuppression. Preoperatively there was no evidence of an associated extracardiac granulomatous disease. Twenty-one months after heart transplantation, giant cell myocarditis recurred in the allograft associated with sustained ventricular arrhythmias. There remained an absence of concomitant extracardiac granulomatous diseases and infections. Increased corticosteroid therapy cleared myocardial inflammation but did not abolish ventricular arrhythmias, which required pharmacologic intervention and the insertion of an Intertach II antitachycardia pacemaker. Compared with a value of 0.56 obtained 1 year after heart transplantation, left ventricular ejection fraction decreased to 0.29 at the time of diagnosis of giant cell myocarditis and remained subnormal 6 months later. Because giant cell myocarditis can recur in the allograft, the candidacy of patients with this disease for heart transplantation must be carefully assessed.

Entities:  

Mesh:

Year:  1992        PMID: 1576144

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

Review 1.  Cardiac Autoimmunity: Myocarditis.

Authors:  William Bracamonte-Baran; Daniela Čiháková
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 2.  Small steps for idiopathic giant cell myocarditis.

Authors:  Jeffrey A Shih; Jennifer A Shih
Journal:  Curr Heart Fail Rep       Date:  2015-06

3.  Fatal giant cell myocarditis after resection of thymoma.

Authors:  P E Glennon; M E Petersen; M N Sheppard
Journal:  Heart       Date:  1996-05       Impact factor: 5.994

Review 4.  Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations.

Authors:  M Sekiguchi; Y Yazaki; M Isobe; M Hiroe
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

5.  Thymoma associated with fatal myocarditis and polymyositis in a 58-year-old man following treatment with carboplatin and paclitaxel: A case report.

Authors:  Hidefumi Sasaki; Motoki Yano; Osamu Kawano; Yu Hikosaka; Yoshitaka Fujii
Journal:  Oncol Lett       Date:  2011-11-30       Impact factor: 2.967

6.  Support with the BVS 5000 assist device during treatment of acute giant-cell myocarditis.

Authors:  Daniel Marelli; Reza Kermani; Jessica Bresson; Michael C Fishbein; Michele Hamilton; Jaime Moriguchi; Gregg C Fonarow; Benjamin Cohen; Jon Kobashigawa; Hillel Laks
Journal:  Tex Heart Inst J       Date:  2003

7.  Idiopathic Giant Cell Myocarditis.

Authors:  Leslie T. Cooper; Yuji Okura
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-12

8.  Monomorphic Ventricular Tachycardia as a Presentation of Giant Cell Myocarditis.

Authors:  Michael H Chiu; Cvetan Trpkov; Saman Rezazedeh; Derek S Chew
Journal:  Case Rep Cardiol       Date:  2019-06-19

9.  A giant mystery in giant cell myocarditis: navigating diagnosis, immunosuppression, and mechanical circulatory support.

Authors:  Julianne M Fallon; Alex M Parker; Steven P Dunn; Jamie L W Kennedy
Journal:  ESC Heart Fail       Date:  2019-12-24

10.  Meeting the Challenges of Myocarditis: New Opportunities for Prevention, Detection, and Intervention-A Report from the 2021 National Heart, Lung, and Blood Institute Workshop.

Authors:  Daniela Čiháková; Yang Shi; Bishow Adhikari; W Patricia Bandettini; Madeleine W Cunningham; Narasimhan Danthi; Matthias G Friedrich; Peter Liu; Lisa Schwartz Longacre; Douglas L Mann; Filip K Swirski; W H Wilson Tang; Guofei Zhou; Leslie T Cooper
Journal:  J Clin Med       Date:  2022-09-27       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.